<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440323</url>
  </required_header>
  <id_info>
    <org_study_id>OXS104094</org_study_id>
    <nct_id>NCT00440323</nct_id>
  </id_info>
  <brief_title>Disturbed Sleep Model Study.</brief_title>
  <official_title>A Double-blind, Double-dummy, Randomised, Placebo-controlled,Four-way Crossover Study to Investigate the Effect of Single Oral Doses of SB-649868 and of Zolpidem in a Model of Noise Induced Situational Insomnia in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be screened within 28 days. Each treatment session will consist of 2 PSG
      nights, study drug administration and noise model is conducted on second night.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2007</start_date>
  <completion_date type="Actual">July 3, 2007</completion_date>
  <primary_completion_date type="Actual">July 3, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Total Sleep Time measured overnight across four treatment sessions (4 weeks)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effects on daytime cognitive function following dosing across four treatment sessions (4 weeks)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>ADBC sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BACD sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBDA sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCAB sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-649868</intervention_name>
    <description>SB-649868 tablets will be available with dose strength of 5 and 25 mg.</description>
    <arm_group_label>DCAB sequence</arm_group_label>
    <arm_group_label>CBDA sequence</arm_group_label>
    <arm_group_label>BACD sequence</arm_group_label>
    <arm_group_label>ADBC sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>Zolpidem capsules will be available with dose strength of 10 mg.</description>
    <arm_group_label>DCAB sequence</arm_group_label>
    <arm_group_label>CBDA sequence</arm_group_label>
    <arm_group_label>BACD sequence</arm_group_label>
    <arm_group_label>ADBC sequence</arm_group_label>
    <other_name>SB-649868</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.</description>
    <arm_group_label>DCAB sequence</arm_group_label>
    <arm_group_label>CBDA sequence</arm_group_label>
    <arm_group_label>BACD sequence</arm_group_label>
    <arm_group_label>ADBC sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight =50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive

          -  Healthy as judged by responsible physician.

          -  No clinically significant abnormality identified on the medical or laboratory
             evaluation and 12-lead ECG;

          -  The subject shows a normal sleep pattern on the basis of the evaluation of both PSG
             screening nights. Normal sleep will be defined as follows: LPS (Latency to persistence
             Sleep) &lt;30min., SE (Sleep Efficiency) &gt;85%, apnea/ hypopnea index &lt; 10, periodic leg
             movements (PLM) with arousal index &lt; 10. The apnea/hypopnea index is defined as &quot;the
             number of apneas and hyponeas divided by the total sleep time (TST) expressed in
             hours&quot;. PLMI is defined as &quot;the number of periodic leg movements associated with
             arousals or awakening divided by the total sleep time (TST) expressed in hour&quot;.

        Exclusion Criteria:

          -  A positive result for the pre-study urine drug/ alcohol breath screen.

          -  Abuse of alcohol.

          -  Subject complains of sleep disturbances and /or is receiving treatment for sleep
             disorders.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/OXS104094?search=study&amp;search_terms=OXS104094#rs</url>
    <description>Results for study OXS104094 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Noise induced Situational insomnia,</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>SB-649868,</keyword>
  <keyword>Zolpidem,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

